Pivotal bioVenture Partners | Activity | F4

Team Portfolio Raise Essays

F4/Pivotal bioVenture Partners/Activity

Pivotal bioVenture Partners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Milestone

Portfolio companies MapLight Therapeutics and Evommune completed successful IPOs.

MapLight Therapeutics and Evommune IPOs

Pivotal bioVenture Partners

pivotallifesciences.comDEC 3, 2025

DEC 3, 2025

Exit

Sanofi completed its acquisition of portfolio company Vigil Neuroscience.

Vigil Neuroscience acquired by Sanofi

Pivotal bioVenture Partners

sanofi.comAUG 6, 2025

AUG 6, 2025

Milestone

Portfolio company MapLight Therapeutics announced a $372.5M Series D financing.

MapLight Therapeutics $372.5M Series D

Pivotal bioVenture Partners

maplightrx.comJUL 28, 2025

JUL 28, 2025

Milestone

Portfolio company Avalyn Pharma completed an oversubscribed $100M Series D.

Avalyn Pharma $100M Series D

Pivotal bioVenture Partners

globenewswire.comJUL 22, 2025

JUL 22, 2025

3 exits· NOV 2024 – JUL 2025Show all

Exit

BioMarin completed its acquisition of portfolio company Inozyme Pharma.

Inozyme Pharma acquired by BioMarin

Pivotal bioVenture Partners

investors.biomarin.comJUL 1, 2025

JUL 1, 2025

Exit

Novartis completed its acquisition of portfolio company Anthos Therapeutics in a deal worth up to $3.1B, $925M upfront.

Anthos Therapeutics acquired by Novartis

Pivotal bioVenture Partners

anthostherapeutics.comAPR 3, 2025

APR 3, 2025

Exit

Portfolio company Exscientia officially combined with Recursion.

Exscientia combined with Recursion

Pivotal bioVenture Partners

ir.recursion.comNOV 20, 2024

NOV 20, 2024

Milestone

Portfolio company Evommune announced a $115M Series C financing.

Evommune $115M Series C

Pivotal bioVenture Partners

prnewswire.comOCT 31, 2024

OCT 31, 2024

Exit

AstraZeneca announced it would acquire portfolio company Fusion Pharmaceuticals.

Fusion Pharmaceuticals acquired by AstraZeneca

Pivotal bioVenture Partners

astrazeneca.comMAR 19, 2024

MAR 19, 2024

New Fund

Closed Fund II at $389M, bringing total bioVenture commitments to $689M.

Pivotal bioVenture Partners Fund II

Pivotal bioVenture Partners

businesswire.comDEC 18, 2023

fiercebiotech.com

DEC 18, 2023